COMPANY PROFILE

Orbis Medicines

Explore full profile

Reshaping the future of drug discovery

Copenhagen, DenmarkFounded 2022Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Orbis Medicines

Orbis Medicines is a biopharmaceutical company focused on the discovery and development of oral macrocycle drugs. The company has developed a technology platform that enables the design and synthesis of these complex molecules, which have the potential to address a wide range of diseases that are currently difficult to treat with conventional small molecule drugs or biologics.

Orbis is using its platform to build a pipeline of oral macrocycle drug candidates for various therapeutic areas. The company's business model is to advance these candidates through preclinical and early clinical development, and then partner with larger pharmaceutical companies for late-stage development and commercialization. Orbis recently secured a significant Series A financing round, which will be used to advance its lead programs and further develop its technology platform.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Copenhagen, Denmark
Employees: 48
Open positions: 1
Dealroom signal: 89.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Medical & Healthcare, Spinout, AI Drug Discovery, Techbio Drug Discovery, DT and LS, science-based
Technology: Artificial Intelligence, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Jan 2025	$99M	$396M	Novo Holdings · Cormorant Asset Management · Eli Lilly · Export and Investment Fund of Denmark	↗
SEEDOther financing	Feb 2024	$29M	$114M	Forbion Capital Partners · Novo Holdings	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Orbis Medicines website traffic

Latest recorded traffic for Orbis Medicines is 4.1K monthly website visits, up 41.4% over the last three months. Orbis Medicines's team grew 9.1% over the past year.

Latest monthly visits4.1K 3-month web change+41.4% 1-year team growth+9.1%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTOLREMO therapeuticsFocused on the discovery and development of small molecules to prevent resistance in cancer therapy	Basel, Switzerland	Operational	16	$47M	$125M
HTHotHouse TherapeuticsAI-driven plant bioengineering for therapeutic molecule discovery	Norwich, United Kingdom	Operational
STScripta TherapeuticsAI-driven drug discovery modulating transcription factor activity	Oxford, United Kingdom	Operational
DADaltontxAdaptive AI platform for pharmaceutical drug discovery	London, United Kingdom	Operational
INInVirtuoLabsModular AI solutions accelerating drug discovery with predictive models and generative simulations	Lugano, Switzerland	Operational
ALALLOXHarnessing the power of genetics and AI to learn the biophysical parameters governing protein function	Barcelona, Spain	Operational
OOOrakl OncologyTumor avatars to transform oncology drug development	Paris, France	Operational
ADAMPLY DiscoveryNovel Biologics. Designed by Evolution. Discovered by AI	Belfast, United Kingdom	Operational